Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.52 |
| ▸ | CXCR1 | P25024 | 13/20 | 0.52 |
| ▸ | CCR6 | P51684 | 3/20 | 0.45 |
| ▸ | CCR7 | P32248 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639810 | 0.89 | CXCR2 (0.59) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12779813 | 0.87 | CXCR1 (0.53) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL12779865 | 0.87 | CXCR2 (0.47) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12779831 | 0.86 | CXCR2 (0.49) | CXCR2CXCR1CCR6 | |
| SCHEMBL13344860 | 0.86 | CXCR2 (0.55) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL13208914 | 0.86 | CXCR2 (0.70) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12779859 | 0.85 | CXCR2 (0.53) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL12779905 | 0.85 | CXCR2 (0.57) | CXCR2CXCR1CCR6CXCR3CCR4 | |
| SCHEMBL13208013 | 0.83 | CXCR2 (0.55) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL14621640 | 0.81 | CXCR2 (0.50) | CXCR2CXCR1CCR6CCR7CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897606-B2 | 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070015731-A1 | 5,6-Di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands | MERCK SHARP & DOHME CORP. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015731-A1 | 5,6-Di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands | CXCR5, CCR5, CXCR1 | CXCR2 4/4885CXCR1 3/4885CCR6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.